Zafgen

Beloranib’s Phase 3 Trial Successful

Beloranib’s Phase 3 Trial Successful

The biopharmaceutical company Zafgen has announced the successful completion of the phase 3 trial of its treatment for an unusual genetic obesity disorder, known as Prader-Willi syndrome. The success comes after the trial of the treatment previously resulted in two deaths.

The Boston-based company’s beloranib has shown effectiveness in reducing weight of people suffering from this syndrome, which results in critical obesity due to intolerable hunger.




Check out More news from Telecom Sector :: Pharmaceutical Sector :: Auto Sector :: Infrastructure :: Real Estate


Syndicate content